Clinical Trial Center, Seoul National University Hospital
Seoul, 110-744, South Korea
NCT Number: NCT02557594
This Phase I clinical study is to evaluate the safety and pharmacokinetics of DA-2802 319mg and Viread 300mg after a single oral dose in healthy male volunteers.
Looking for future studies?
Notify Me20 year–50 year
Male
Interventional
Phase 1
Seoul, 110-744, South Korea
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
single dose administration after 10hr fasting
Other names: Tenofovir disoproxil fumarate
single dose administration after 10hr fasting
Other names: Tenofovir disoproxil orotate
Time frame: 0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose
Time frame: 0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose
Time frame: 0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose
Time frame: 0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose
Time frame: 0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose
Time frame: 0h(before admisitration), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72h post-dose
Dong-A ST Co., Ltd.
Industry
A Randomized, Open-label, Two-way Crossover Study to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg After a Single Oral Dose in Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06901362
Blood-Borne Infections, Chickenpox
Pathum Thani, Changwat Pathum Thani, Thailand
View Trial DetailsNCT04297917
Blood-Borne Infections, Communicable Diseases
Southampton, Hampshire, United Kingdom
View Trial DetailsNCT04109625
Blood-Borne Infections, Communicable Diseases
Grenoble, France
View Trial DetailsNCT02117934
Blood-Borne Infections, Communicable Diseases
Birmingham, Alabama, United States
View Trial Details